Impact of temporomandibular disorder comorbidity on pain, quality of life, sleep, and functional outcomes in chronic migraine patients not using preventive treatment: a cross-sectional study
Abstract
ABSTRACT Objectives To investigate pain, quality of life, sleep, and functional outcomes between chronic migraine (CM) patients with temporomandibular disorder (TMD) and patients with CM alone. Methods Thirty one patients with CM and thirty one patients with CM+TMD were recruited in the study. All patients had not been on preventive treatment for CM or TMD in the previous three months. TMD was examined by physical examination, guided by the subdomains of the Helkimo Clinical Dysfunction Index (HCDI). All patients were evaluated for allodynia using the Allodynia Symptom Checklist (ASC-12), quality of life using the 36-item Short Form Health Survey (SF-36), headache-related disability using the Migraine Disability Assessment Scale (MIDAS) and the Headache Impact Test (HIT-6), and sleep quality using the Pittsburgh Sleep Quality Index (PSQI). Results The average pain intensity was higher in patients with CM+TMD (p < 0.001). The number of patients with a migraine attack duration of more than 3 days were significantly higher in the same group (p = 0.001). ASC-12 scores were significantly elevated in patients with CM+TMD (p < 0.001). MIDAS and HIT-6 scores were significantly higher in the CM+TMD patient group (p = 0.010, p < 0.001, respectively). HCDI score was significantly positively correlated with age, BMI, average number of headache days in a month, ASC-12 score, PSQI sleep disturbance domain score, and PSQI total score (r = 0.625, 0.406, 0.417, 0.484, 0.499, and 0.487,…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.